Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. (1st November 2020)

• Record Type: Journal Article
• Authors: Milic, Jovana; Menozzi, Valentina; Schepis, Filippo; Malagoli, Andrea; Besutti, Giulia; Franconi, Iacopo; Raimondi, Alessandro; Carli, Federica; Mussini, Cristina; Sebastiani, Giada; Guaraldi, Giovanni
• Is Part Of: AIDS. Volume 34:Number 13(2020)
• Publication Date: 2020-11-01
• Subjects: frailty -- HIV -- nonalcoholic fatty liver disease -- nonalcoholic steatohepatitis; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000002650
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018–2019. Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP ≥248 dB/m), while significant liver fibrosis or cirrhosis (stage ≥F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4 + cell count 700 cells/μl, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6–15], vitamin D insufficiency (OR = 1.94, 1.2–3.2), obesity (OR = 8.1, 4.4–14.6), diabetes (OR = 3.2, 1.9–5.6), metabolic syndrome (OR = 2.41, 1.47–3.95) and osteoporosis (OR = 0.37, 0.16–0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3–3.5), fibrosis (OR = 2, 1–3.7), NAFLD with fibrosis (OR = 9.2, 5.2–16.8), diabetes (OR = 1.7, 1–2.7) and multimorbidity (OR = 2.5, 1.5–4). Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH.